Alzinova AB (publ) (ALZ.ST) Research

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.

Market snapshot

Symbol
ALZ.ST
Price
$0.48
Day change
-0.10%
Market cap
$50.1M
P/E ratio
-1.84x
52-week range
0.382-2.28
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • AcuCort AB (ACUC.ST)
  • Annexin Pharmaceuticals AB (publ) (ANNX.ST)
  • BrainCool AB (publ) (BRAIN.ST)
  • Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
  • Isofol Medical AB (publ) (ISOFOL.ST)
  • Klaria Pharma Holding AB (publ.) (KLAR.ST)
  • Lipum AB (publ) (LIPUM.ST)
  • Nanologica AB (publ) (NICA.ST)

Open Alzinova AB (publ) (ALZ.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.